Abstract
MiRNA is a class of small non-coding RNA molecule that regulates gene expression at post-transcriptional level. Increasing evidences show aberrant expression of miRNAs in a variety of diseases. Targeting the dysregulated miRNAs with small molecule drugs has become a novel therapeutics for many human diseases, especially cancers. In this chapter, we introduced a series of computational studies for prediction of small molecule and miRNA associations. Based on different hypotheses, such as transcriptional response similarity, functional consistence or network closeness, the small molecule-miRNA networks were constructed and further analyzed. In addition, several resources that collected experimentally validated relationships or computational predicted associations between small molecules and miRNAs were provided. Collectively, these computational frameworks and databases pave a new way for miRNA-targeted therapy and drug repositioning.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Drews J, Ryser S (1997) The role of innovation in drug development. Nat Biotechnol 15(13):1318–1319
Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5(12):993–996
Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1(9):727–730
Garzon R, Marcucci G, Croce CM (2010) Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 9(10):775–789
Schmidt MF (2014) Drug target miRNAs: chances and challenges. Trends Biotechnol 32(11):578–585
Ling H, Fabbri M, Calin GA (2013) MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 12(11):847–865
Gebert LF et al (2014) Miravirsen (SPC3649) can inhibit the biogenesis of miR-122. Nucleic Acids Res 42(1):609–621
Lanford RE et al (2010) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327(5962):198–201
Bose D et al (2012) The tuberculosis drug streptomycin as a potential cancer therapeutic: inhibition of miR-21 function by directly targeting its precursor. Angew Chem Int Ed Eng 51(4):1019–1023
Monroig Pdel C et al (2015) Small molecule compounds targeting miRNAs for cancer therapy. Adv Drug Deliv Rev 81:104–116
Vo DD et al (2014) Targeting the production of oncogenic microRNAs with multimodal synthetic small molecules. ACS Chem Biol 9(3):711–721
Jamal S, Periwal V, Scaria V (2012) Computational analysis and predictive modeling of small molecule modulators of microRNA. J Cheminform 4(1):16
Zhang S et al (2010) Targeting microRNAs with small molecules: from dream to reality. Clin Pharmacol Ther 87(6):754–758
Bose D et al (2013) A molecular-beacon-based screen for small molecule inhibitors of miRNA maturation. ACS Chem Biol 8(5):930–938
Sirota M et al (2011) Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 3(96):96ra77
Dudley JT et al (2011) Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med 3(96):96ra76
Iorio F et al (2010) Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A 107(33):14621–14626
Jiang W et al (2012) Identification of links between small molecules and miRNAs in human cancers based on transcriptional responses. Sci Rep 2:282
Lamb J et al (2006) The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313(5795):1929–1935
Rhodes DR et al (2007) Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9(2):166–180
Meng F et al (2016) Psmir: a database of potential associations between small molecules and miRNAs. Sci Rep 6:19264
Wang J et al (2016) Identification of associations between small molecule drugs and miRNAs based on functional similarity. Oncotarget 7(25):38658–38669
Frohlich H et al (2007) GOSim – an R-package for computation of information theoretic GO similarities between terms and gene products. BMC Bioinformatics 8:166
Alexa A, Rahnenfuhrer J, Lengauer T (2006) Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. Bioinformatics 22(13):1600–1607
Yu G et al (2010) GOSemSim: an R package for measuring semantic similarity among GO terms and gene products. Bioinformatics 26(7):976–978
Lv Y et al (2015) Identifying novel associations between small molecules and miRNAs based on integrated molecular networks. Bioinformatics 31(22):3638–3644
Liu X et al (2013) SM2miR: a database of the experimentally validated small molecules’ effects on microRNA expression. Bioinformatics 29(3):409–411
Yang Q et al (2011) miREnvironment database: providing a bridge for microRNAs, environmental factors and phenotypes. Bioinformatics 27(23):3329–3330
Barh D, Bhat D, Viero C (2010) miReg: a resource for microRNA regulation. J Integr Bioinform 7(1):144
Rukov JL et al (2014) Pharmaco-miR: linking microRNAs and drug effects. Brief Bioinform 15(4):648–659
Wahlestedt C (2013) Targeting long non-coding RNA to therapeutically upregulate gene expression. Nat Rev Drug Discov 12(6):433–446
Wheeler TM et al (2012) Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488(7409):111–115
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Jiang, W., Lv, Y., Wang, S. (2018). Prediction of Non-coding RNAs as Drug Targets. In: Li, X., Xu, J., Xiao, Y., Ning, S., Zhang, Y. (eds) Non-coding RNAs in Complex Diseases. Advances in Experimental Medicine and Biology, vol 1094. Springer, Singapore. https://doi.org/10.1007/978-981-13-0719-5_11
Download citation
DOI: https://doi.org/10.1007/978-981-13-0719-5_11
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-0718-8
Online ISBN: 978-981-13-0719-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)